Quarterly report · Q2
2531.TEDINET S100S6LP
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥163.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥350.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥164.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥12.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥19.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥13.0bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥38.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.0bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥13.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥20.8bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥8.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥21.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥10.9bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥9.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥14.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥420.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥399.2bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥366.3bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥148.8bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥143.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥272.1bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥255.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥244.3bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥89.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥96.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥84.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥91.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥56.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥75.7bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥14.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥45.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥15.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥9.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥21.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥40.69 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.57 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.26 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.48 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 52.2% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥14.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥6.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥8.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥9.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥9.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥348m |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥77.2bn |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥76.9bn |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥282m |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.3bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥19.1bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥19.1bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥61.2bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥60.7bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥486m |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥157.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥156.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥768m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥11.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥172.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥163.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥12.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥15.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥8.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥9.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥9.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥216m |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥63.7bn |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥63.6bn |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥121m |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥32.6bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥32.6bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥10.9bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥61.8bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥61.3bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥483m |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥158.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥157.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥608m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥18.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥173.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥164.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥9.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥19.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 519
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 6749000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 164279000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 164279000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraShuzoGroupReportableSegmentsMember | 483000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraBioGroupReportableSegmentsMember | 121000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraHealthcareReportableSegmentsMember | 2000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 608000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 8827000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9435000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -9435000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraShuzoGroupReportableSegmentsMember | 61820000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraBioGroupReportableSegmentsMember | 63730000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraHealthcareReportableSegmentsMember | 32587000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 158138000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 15577000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 173715000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -9435000000 | JPY |
| Net sales | Prior1YTDDuration | 164279000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraShuzoGroupReportableSegmentsMember | 2059000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraBioGroupReportableSegmentsMember | 5658000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00396-000TakaraHealthcareReportableSegmentsMember | 10870000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 18588000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1243000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 19831000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -216000000 | JPY |
| Operating income | Prior1YTDDuration | 19614000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraShuzoGroupReportableSegmentsMember | 60704000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraBioGroupReportableSegmentsMember | 76881000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraHealthcareReportableSegmentsMember | 19116000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 156702000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 6470000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 163172000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 163172000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraShuzoGroupReportableSegmentsMember | 486000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraBioGroupReportableSegmentsMember | 282000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraHealthcareReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 768000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 8396000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 9165000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -9165000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraShuzoGroupReportableSegmentsMember | 61190000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraBioGroupReportableSegmentsMember | 77164000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00396-000TakaraHealthcareReportableSegmentsMember | 19116000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 157471000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 14866000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 172338000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |